Navigation Links
Novagali Pharma Announces the Launch of Cationorm(R)
Date:4/9/2008

The Innovative Cationic Emulsion for the Treatment of Dry Eye Symptoms

An Optimal Solution for Patients

The First Product Developed From its Pipeline to be Marketed

EVRY, France, April 9 /PRNewswire/ -- Novagali Pharma, an ophthalmic specialty pharmaceutical company announces the commercial launch in France of its first product Cationorm(R). This cationic emulsion is an innovative approach to treat dry eye symptoms. It has been developed on the basis of Novagali Pharma patented technology platform Novasorb(R).

Dry eye syndrome is the second cause of consultation in ophthalmology. It concerns over 100 million people in the world and 14% of the adults of more than 40 years. Due to a chronic lack of lubrication and moisture in the eye, its consequences range from irritation to ocular inflammation of the conjunctiva and corneal tissues of the eyes. People with dry eye have sandy-gritty irritation or burning in their eyes. In most severe cases, corneal lesions may lead to vision loss. Specific factors such as ageing populations, pollution, air conditioning, extended use of computers, contribute to an increase in the prevalence of the syndrome and in opportunities for the development of more efficient products.

Cationorm(R) brings a true innovation to the patients suffering from dry eye symptoms. The cationic emulsion reproduces the tear mechanisms of action to act on the different levels of the tear film. Cationorm(R) uniquely combines lubricating and hydrating properties, optimal spreading on the surface of the eye, replenishment of the tear film lipid layer and prevention of tear evaporation. The results of clinical study have clearly demonstrated Cationorm(R) advantages for patients: tolerance, long-lasting relief and optimal comfort.

These advantages are based on Novasorb(R), the proprietary cationic emulsion technology platform of Novagali Pharma. Novasorb(R), is designed to improve topical administration of ophthalmic medicines. It is based on the electrostatic attraction that occurs between the droplets of a positively-charged emulsion and the negatively charged cells of the ocular surface, including cornea and conjunctiva.

The commercial launch of Cationorm(R) in Europe and in the United States by the end 2008, where the product complies with the OTC status, is a major event for the development of Novagali Pharma. <>, said Jerome Martinez, CEO of Novagali Pharma.

Cationorm(R) is a medical device available in France since April 2008. The product is unpreserved and packaged in box of 30 sterile single vials.

A propos de Novagali Pharma : http://www.novagali.com

Novagali Pharma is an ophthalmic pharmaceutical company based in the Genopole biocluster in Evry (France) that develops and commercializes innovative products. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of 7 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis, Cyclokat(R), a product for the treatment of moderate-to-severe dry eye syndrome and Cortiject(R) for the treatment of diabetic retinopathies. Cationorm(R), indicated for dry eye symptoms is commercialized in France since April 2008. Founded in 2000, Novagali Pharma has 50 employees.


'/>"/>
SOURCE Novagali Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 08, 2016 , ... Thomas J. Todorow has joined the ... for Corporate Services and the Chief Financial Officer at The Children’s Hospital of ... Managed Care Contracting, Supply Chain, and Investments. , Prior to joining CHOP and ...
(Date:2/8/2016)... , ... February 08, 2016 , ... Information Management Services ... product. The upgrade represents a completely new technical foundation and is so significant ... a responsive design interface, significantly increased speed for search results, a streamlined layout and ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... and leading supplier of Semantic Graph Database technology, today announced the availability of ... of Cloudera Enterprise through the Cloudera Certified Technology Program (CCPT). AllegroGraph ...
(Date:2/8/2016)... has an active R&D program for the development of future ... has a unique research and development center in ... Control products. Stockton has a variety ... guidelines, and is active in more than 35 counties worldwide. ... Stockton,s flagship product Timorex Gold ® is ...
Breaking Biology Technology:
(Date:2/1/2016)... February 1, 2016 Rising sales ... drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new technological ... size through 2020   ... with new technological advancements to drive global touchfree intuitive ...
(Date:1/28/2016)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human ... December 31, 2015. --> --> ... 2 percent compared to the comparable quarter last year to $470.5 ... $35.0 million, or $0.93 per diluted share. ... quarter of fiscal 2016 grew 9 percent over the prior year ...
(Date:1/25/2016)... Software, the world-leading supplier of image data management solutions ... data management solution OMERO Plus for the newly established ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... analysis measures the characteristics and behavior of cells, tissues ... as health and disease, the presence or absence of ...
Breaking Biology News(10 mins):